Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03580564CT.gov An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Classic Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Kl-A167 (this asset) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | P2 | CCC · 52 |
| Dacarbazine | City of Hope Medical Center | P3 | BB |
| Etoposide | Masonic Cancer Center, University of Minnesota | P3 | BB |
| Vinblastine | University of Washington | P2 | BB |
| Adriamycin | Michael Spinner, MD | P3 | BB |
| Tislelizumab | Children's Cancer Group, China | P3 | BB |
| Cyclophosphamide | National Cancer Institute (NCI) | P3 | BB |
| Brentuximab Vedotin | National Cancer Institute (NCI) | P3 | BB |
| Pembrolizumab | National Cancer Institute (NCI) | P3 | B |
+42 more in the Classic Hodgkin Lymphoma cohort
Other indications for Kl-A167
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Small Cell Lung Carcinoma | — | P2 | CC · 45 |
| Non-Small Cell Lung Carcinoma | — | P2 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Kl-A167 in Classic Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/kl-a167-classic-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →